C. Huff

发表

Lenalidomide-induced acute interstitial nephritis.

E. Lipson, C. Huff, D. Holanda, 2010, The oncologist.

Identifying Indicators of Outcomes and Implementing Treatment Pathways

C. Huff, J. Dunn, 2015 .

Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma

C. Huff, F. Parhami, A. Merchant, 2014, Molecular Cancer Therapeutics.

Multiple myeloma cancer stem cells.

C. Huff, W. Matsui, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thrombotic Microangiopathy After Post-Transplantation Cyclophosphamide-Based GVHD Prophylaxis.

R. Varadhan, C. Huff, Richard J. Jones, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

G. Rosner, C. Huff, M. Zahurak, 2017, Blood advances.

A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

C. Huff, J. Walczak, M. Carducci, 2004 .

Severe cytokine release syndrome after haploidentical peripheral blood transplantation.

C. Huff, Richard J. Jones, D. Gladstone, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

G. Rosner, C. Huff, D. Pardoll, 2015, Science Translational Medicine.

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, Christopher G. Kanakry, G. Rosner, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NCCN clinical practice guidelines in oncology: multiple myeloma.

J. Vose, K. Anderson, S. Singhal, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

S. Singhal, Rashmi Kumar, C. Huff, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia

Steve Y. Cho, C. Huff, M. Borowitz, 2013, Leukemia & lymphoma.

Recrudescence of cutaneous Mycobacterium haemophilum lesions following tetanus immunization.

C. Huff, J. Cofrancesco, M. K. Gibson, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multiple Myeloma: Current Advances and Future Directions.

C. Huff, T. Martin, 2019, Clinical lymphoma, myeloma & leukemia.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

R. Varadhan, C. Huff, M. Perales, 2023, The New England journal of medicine.

Comment on research report by Gruson and colleagues, this issue

C. Huff, R. Hughes, D. Cornblath, 2011, Journal of the peripheral nervous system : JPNS.

The paradox of response and survival in cancer therapeutics.

C. Huff, Richard J. Jones, B. Smith, 2006, Blood.

Multiple Myeloma Stem Cells and Plasma Cells Display Distinct Drug Sensitivities.

C. Huff, Richard J. Jones, B. Smith, 2004 .

Systemic Light Chain Amyloidosis - Panel Members

A. Krishnan, S. Singhal, C. Huff, 2014 .

Multiprofessional Ward Rounds for Inpatients With Advanced Cancers: Too Big to Succeed?

P. Pronovost, C. Huff, W. G. Nelson, 2018, Journal of oncology practice.

Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.

C. Huff, L. Gondek, Richard J. Jones, 2020, Blood advances.

High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.

Allen R. Chen, S. Goodman, C. Huff, 2010, Blood.

Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.

G. Rosner, C. Huff, M. Zahurak, 2020, Blood advances.

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

S. Jagannath, D. Siegel, R. Vij, 2018, British journal of haematology.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

R. Varadhan, C. Huff, M. Zahurak, 2017, Blood.

Increasing the dose of total body irradiation to decrease graft failure associated with HLA-haploidenticaltransplantation for patients with severe hemoglobinopathies. A single institution prospective clinical trial

C. Huff, Richard J. Jones, D. Gladstone, 2019 .

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

G. Ahmann, R. Fonseca, S. Jagannath, 2016 .

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

G. Ahmann, R. Fonseca, S. Jagannath, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

C. Huff, J. Lode, J. Kowalski, 2010 .

Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms

C. Harley, C. Huff, Richard J. Jones, 2010, PloS one.

The Immunomodulatory Role of Lenalidomide on Prevnar® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response

C. Huff, I. Borrello, R. Knight, 2008 .

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Changes in photo-aged human skin following topical application of all-trans retinoic acid.

C. Huff, T. Hamilton, J. Voorhees, 1990, The Journal of investigative dermatology.

High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas

I. Flinn, C. Huff, M. Zahurak, 2011, Leukemia & lymphoma.

A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.

C. Huff, P. Greipp, H. Lazarus, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

C. Huff, Richard J. Jones, Carole B. Miller, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone marrow transplantation for multiple myeloma: where we are today

C. Huff, Richard J. Jones, 2002, Current opinion in oncology.

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

C. Huff, Richard J. Jones, H. Mostafa, 2022, Open forum infectious diseases.

Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Brian S. Iglehart, C. Huff, Richard J. Jones, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Allen R. Chen, S. Piantadosi, C. Huff, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Multiple myeloma

S. Singhal, C. Huff, G. Tricot, 2001, Bone Marrow Transplantation.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2019, The New England journal of medicine.

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

C. Huff, Richard J. Jones, B. Smith, 2008, Cancer research.

Characterization of clonogenic multiple myeloma cells.

C. Huff, Richard J. Jones, B. Smith, 2004, Blood.

Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.

C. Huff, M. Borowitz, Richard J. Jones, 2008, Leukemia research.

Expanding the spectrum of monoclonal light chain deposition disease in muscle

A. Mammen, C. Huff, J. Carrino, 2012, Muscle & nerve.

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.

P. L. Bergsagel, C. Huff, Yiting Lim, 2014, Blood.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

C. Hofmeister, A. Krishnan, S. Singhal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70.

R. Varadhan, C. Huff, Richard J. Jones, 2019, Blood advances.

Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia

C. Huff, Richard J. Jones, W. Matsui, 2005, British journal of haematology.

Posttransplantation Cyclophosphamide-based Graft versus Host Disease Prophylaxis with Non-myeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis.

R. Varadhan, C. Huff, L. Gondek, 2022, Transplantation and cellular therapy.

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

C. Huff, P. Beachy, D. N. Watkins, 2007, Proceedings of the National Academy of Sciences.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

Shannon R. McCurdy, G. Rosner, C. Huff, 2017, Haematologica.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Blood.

Updates to the NCCN Guidelines

A. Krishnan, S. Singhal, C. Huff, 2013 .

Properties , and Drug Resistance Clonogenic Multiple Myeloma Progenitors , Stem Cell

C. Huff, Richard J. Jones, B. Smith, 2007 .

Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.

R. Varadhan, C. Huff, L. Gondek, 2021, Clinical lymphoma, myeloma & leukemia.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

C. Huff, J. Kowalski, Richard J. Jones, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

C. Huff, Richard J. Jones, D. Gladstone, 2019, The Lancet. Haematology.

Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide.

G. Rosner, C. Huff, M. Zahurak, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

G. Rosner, C. Huff, M. Zahurak, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Shannon R. McCurdy, G. Rosner, C. Huff, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

I. Flinn, C. Huff, Richard J. Jones, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Allen R. Chen, S. Goodman, C. Huff, 2010, Blood.

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

C. Huff, Richard J. Jones, D. Gladstone, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide.

C. Huff, M. Zahurak, Richard J. Jones, 2021, Transplantation and cellular therapy.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

G. Rosner, C. Huff, M. McDevitt, 2014, Blood.

Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.

Shannon R. McCurdy, R. Varadhan, C. Huff, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Blood or Marrow Transplantation with High-Dose Post-transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Aged ≥55.

R. Varadhan, C. Huff, C. Hourigan, 2022, Transplantation and cellular therapy.

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.

R. Varadhan, C. Huff, Richard J. Jones, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose cyclophosphamide as single agent, short-course prophylaxis of graft-

Allen R. Chen, C. Huff, M. Zahurak, 2017 .

Anti‐tumour activity of interferon‐alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation

C. Huff, Richard J. Jones, B. Smith, 2003, British journal of haematology.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

J. Witte, M. Lieber, G. Colditz, 2016, Cancer Epidemiology, Biomarkers & Prevention.

An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission

M. Vignali, C. Huff, C. Sanders, 2021, Clinical Cancer Research.

Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide

G. Rosner, C. Huff, M. Zahurak, 2016, Leukemia & lymphoma.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

J. Witte, G. Colditz, A. Olshan, 2020, Blood advances.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

L. Trippa, N. Munshi, J. Laubach, 2019, Blood.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma

L. Trippa, N. Munshi, J. Laubach, 2018, British journal of haematology.

Multiple myeloma, version 1.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity.

C. Huff, D. Cornblath, I. Borrello, 2006 .

Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients.

C. Huff, K. Carroll, D. Hanna, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

Rashmi Kumar, C. Huff, M. Liedtke, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal

C. Huff, W. Matsui, I. Borrello, 2016, Molecular Cancer Therapeutics.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

G. Rosner, C. Huff, Richard J. Jones, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A human epidermal differentiation-specific keratin gene is regulated by calcium but not negative modulators of differentiation in transgenic mouse keratinocytes.

C. Huff, P. Steinert, D. Roop, 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.

I. Flinn, C. Huff, Richard J. Jones, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

C. Huff, I. Borrello, K. Noonan, 2012, Clinical Cancer Research.

Should MAGE be the rage in myeloma

C. Huff, J. Karp, 2005 .

Multiple myeloma. Clinical practice guidelines in oncology.

J. Vose, S. Singhal, C. Huff, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study

R. Varadhan, C. Huff, Richard J. Jones, 2022, Leukemia & lymphoma.

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen

C. Huff, Richard J. Jones, B. Smith, 2009, Bone Marrow Transplantation.

Oncology Pharmacy Management and the Evolving Role of Managed Care: Recommendations for a Changing Environment with a Focus on Multiple Myeloma

C. Mullins, C. Huff, J. Dunn, 2012, Journal of Managed Care Pharmacy : JMCP.

Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma

C. Huff, M. Zahurak, N. Ghosh, 2014, American journal of hematology.

Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma

C. Huff, X. Ye, N. Ghosh, 2011, British journal of haematology.

Strategies to eliminate cancer stem cells: clinical implications.

C. Huff, Richard J. Jones, B. Smith, 2006, European journal of cancer.

Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors

C. Huff, Richard J. Jones, C. Griffin, 2005, British journal of haematology.

Allogeneic Blood or Marrow Transplantation with Post-transplantation Cyclophosphamide for Peripheral T-cell Lymphoma: The Importance of Graft Source.

R. Varadhan, C. Huff, Richard J. Jones, 2022, Transplantation and cellular therapy.

Allogeneic bone marrow transplantation (ALLO BMT): Role of t cell depletion (TCD) and graft versus host disease (GVHD)

C. Huff, Richard J. Jones, E. Fuchs, 2000 .

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

N. Munshi, C. Huff, A. Chanan-Khan, 2008 .

Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors.

C. Huff, D. Hanna, K. Marr, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

Rashmi Kumar, C. Huff, M. Liedtke, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.

G. Colditz, C. Haiman, D. Auclair, 2020, JCO oncology practice.

HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)

G. Colditz, C. Haiman, L. Kolonel, 2016 .

Administration Of An Oral PDE5 Inhibitor, Tadalafil In Conjunction With a Lenalidomide Containing Regimen In Patients With Multiple Myeloma

C. Huff, X. Ye, N. Ghosh, 2013 .

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

Using Continuing Medical Education to Promote Shared Decision-Making in Patients Diagnosed with Multiple Myeloma

C. Huff, Shaji K. Kumar, K. Obholz, 2016 .

Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

M. Dimopoulos, S. Jagannath, R. Vij, 2018, Blood.

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

C. Huff, Richard J. Jones, J. Powell, 2011 .

IBRUTinib: BRUTe force against bortezomib-resistant myeloma cells

C. Huff, L. Resar, L. Xian, 2015, Cell cycle.

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

G. Gudi, C. Huff, M. Mohty, 2022, Blood.

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines.

C. Huff, P. Schafer, I. Borrello, 2009 .

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, The Journal of the National Comprehensive Cancer Network.

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Blood.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Blood.

Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Rashmi Kumar, C. Huff, M. Liedtke, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, C. Huff, Richard J. Jones, 2014 .

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

C. Huff, Lixin Lang, L. Camacho, 2011 .